Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Continuous professional development: elevating thoracic oncology education in Europe

Wouter H. van Geffen, Torsten G. Blum, Stefano Aliberti, Kevin G. Blyth, Clementine Bostantzoglou, Amy Farr, Bogdan Grigoriu, Georgia Hardavella, Rudolf M. Huber, Nick Maskell, Gilbert Massard, Najib M. Rahman, Daiana Stolz, Jan van Meerbeeck
Breathe 2019 15: 279-285; DOI: 10.1183/20734735.0296-2019
Wouter H. van Geffen
1Dept of Pulmonary Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wouter H. van Geffen
Torsten G. Blum
2Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: torsten-gerriet.blum@helios-gesundheit.de
Stefano Aliberti
3Dept of Pathophysiology and Transplantation, University of Milan, Milan, Italy
4Respiratory Dept, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stefano Aliberti
Kevin G. Blyth
5Glasgow Pleural Disease Unit, Queen Elizabeth University Hospital Glasgow, Glasgow, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clementine Bostantzoglou
67th Respiratory Medicine Dept and Asthma Center, Athens Chest Hospital “Sotiria”, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Farr
7European Respiratory Society, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bogdan Grigoriu
8Service de médecine interne, Institut Jules Bordet, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georgia Hardavella
910th Dept of Respiratory Medicine, Athens Chest Diseases Hospital “Sotiria”, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rudolf M. Huber
10Thoracic Oncology Centre Munich, University of Munich, Munich, Germany, member of the German Center for Respiratory Research (DZL–CPC-M)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rudolf M. Huber
Nick Maskell
11Academic Respiratory Unit, University of Bristol, Bristol, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilbert Massard
12Service de Chirurgie Thoracique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Najib M. Rahman
13Oxford Centre for Respiratory Medicine, University College, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daiana Stolz
14Clinic for Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan van Meerbeeck
15Dept of Pulmonology, Antwerp University Hospital, Edegem, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The @EuroRespSoc launches a new thoracic oncology continuous professional development programme http://bit.ly/31ShuTp

Thoracic oncology encompasses a broad spectrum of primary tumour entities originating from various pulmonary, tracheobronchial, pleural, mediastinal and chest wall tissues or distinct cell types within these compartments. Lung cancer represents by far the most frequent malignant tumour within the thoracic cavity, and is the most common type and largest killer among all cancers worldwide. Lung cancer leads mortality statistics in Europe, accounting for at least one fifth of all cancer-related deaths [1]. In addition, lung cancer causes a significant burden of symptoms in a population of patients with high comorbidity, providing significant challenges to national healthcare systems in the European Union, with the highest overall costs among all cancer types [2–4]. Contrary to the general stigma applied to lung cancer patients, where they are often assumed to suffer from a self-inflicted disease, it is now estimated that up to 10–20% of lung cancer patients are never-smokers [5, 6]. Even if numerically far lower, the remaining <5% of primary thoracic malignancies other than lung cancer challenge thoracic oncology specialists, as well general pulmonologists, often in daily practice, be they pleural mesotheliomas, thymic or neuroendocrine tumours, sarcomas or rare entities such as germ-cell tumours [7, 8].

Epoch-making progress has been made recently in thoracic oncology after decades of only minor improvements regarding prognosis. Nowadays, detailed molecular tumour profiling has led to personalised diagnostic–therapeutic sequences. In addition, immunotherapy is developing as the most exciting and fundamental turning point in the history of lung cancer treatment. In 2009, when this step-change in highly effective therapeutic approaches was not yet foreseeable, the European Respiratory Society (ERS) implemented the far-sighted decision to create its own Thoracic Oncology Assembly. The first step of a detailed, forward-looking action plan was launched in 2010 [9]. In subsequent years, the role of the pulmonologist as pilot and partner in thoracic oncology has been introduced by the American Thoracic Society and the ERS [10].

Against this background, the Thoracic Oncology Assembly has been able to create a basis for standard educational formats and activities in line with the overall ERS strategy over the last few years. Amongst other initiatives, particularly the HERMES (Harmonised Education in Respiratory Medicine for European Specialists) programme for Thoracic Oncology, this has provided a comprehensive template in the field and is recognised worldwide as a role model [11–13]. Given the currently hyperdynamic environment, the Thoracic Oncology Assembly now faces the fascinating opportunity to promote an adapted action plan. While scientific, diagnostic and therapeutic advances are evolving rapidly, the European routine care landscape in thoracic oncology is characterised by a vast heterogeneity in available resources as well as in responsible professionals. The field of systemic therapies for patients with thoracic malignancies is one clear example: in about half of European countries, the involvement of pulmonologists in systemic therapy is essential, contrasting with a significant number of nations in which pulmonologists are neither specifically trained nor active in this area [14]. Scientific progress does not pay any attention to currently established core pneumological skills in thoracic oncology. Rather, it may be envisaged that endoscopic methods will become insignificant in the medium term through the ongoing evolution of sometimes co-equal noninvasive diagnostic measures, namely the increasing maturity of liquid biopsies [15]. The advent of high-quality data demonstrating mortality reduction with lung cancer screening poses a separate but enormous challenge in quality control, implementation and rational delivery of a programme, which may transform our approach to lung cancer. Thus, there is to date an inadequately addressed need for continuous professional development (CPD) among pulmonologists to keep pace with the revolutionary trends in thoracic oncology.

An innovative campaign towards a joint and vivid educational platform in thoracic oncology

The answer to these demanding challenges is firstly one of communication. Analogous to the ERS master plan for other respiratory disease areas, our present educational thoracic oncology platform will be transformed stepwise from a fixed masterpiece to a dynamically adapting up-to-date platform. This new and unique platform is meant to arouse true thirst for knowledge in both general and specialised clinicians, and furthermore, to enable realistic, targeted CPD tailored to personal needs and individual professional career stages.

This document highlights the essential steps from the development towards the aspired implementation of the new ERS educational programme in thoracic oncology, and provides insights into the underlying CPD syllabus, planned educational contents and formats as well as specific communication strategies.

From our mission to strengthen and improve the diagnosis and care of thoracic malignancies in Europe, we envisage an adaptive and evidence-based CPD matrix based on multidisciplinary education. Our educational campaign seeks to cover the entire continuum of thoracic malignancy. We aim to provide attractive educational formats to all physicians and allied health professionals with an interest in thoracic oncology, independent of original discipline, grade of specialisation or current career status. Multidimensional collaboration within and outside the ERS is key to achieve these ambitious goals, namely by:

  • Horizontal linkage with other related ERS assemblies

  • Ensuring multiprofessionality and patient representation by incorporating allied respiratory professionals and the European Lung Foundation, respectively

  • Cooperation with other dedicated international partner societies in the field of thoracic oncology (i.e. the European Society of Radiology, the European Society of Thoracic Surgeons and the International Association for the Study of Lung Cancer)

  • Vertical liaison with respiratory societies and thoracic oncology services on the national and local levels, aiming to set up a harmonised framework of thoracic oncology education and its better implementation throughout Europe, both in countries with higher and lower financial capacities

To adequately meet the varying interests and expectations of the aforementioned targeted individuals, we will perform regular need assessments via surveys and other social media means, from which we will derive target group-specific educational formats. Feedback loops will be used to improve the future quality of our CPD programme, including the involved faculty. Likewise, we will constantly track and appraise new scientific and political developments in the field of thoracic oncology in order to provide up-to-date and evidence-based professional development.

Contextual basis and educational formats

We will use our thoracic oncology CPD syllabus as the contextual basis of our educational programme. This recently developed catalogue stretches from carcinogenesis, through symptoms, imaging, multidisciplinary team care, systemic therapy and malignant pleural effusion, covering the thoracic oncology trajectory in 32 modules as shown in table 1. Each module has been created via a fixed route: design, creation, internal revision, adaptation, external revision and final adaptation. Each module will be maintained and regularly updated according to future developments by a faculty composed of early career members and senior scientific specialists in thoracic oncology.

View this table:
  • View inline
  • View popup
Table 1

Module-based CPD training

The platform used to provide these thoracic oncology educational modules is a comprehensive and adaptive international learning hub with the application of new digital techniques provided by the ERS. We will apply new and well-established ERS educational formats, particularly the following.

  • Electronic learning: continuing medical education (CME) online modules and CME tests

  • ERS courses: skills and online

  • Online and printed publications: ERJ Open Research, the European Respiratory Review, Breathe and the ERS Monograph, with a longer-term aim of introducing an ERS Handbook of Thoracic Oncology

  • Events: ERS International Congress, satellite meetings, research seminars, ERS Live and Best of ERS

  • Online blogs: ERS Respiratory Digest

  • Social media: quizzes

  • HERMES examinations

We will involve prestigious senior faculty and Europe's top-tier thoracic oncology services, but also provide committed early career members with sufficient opportunities to participate in our educational formats, since the latter represent our future.

A general description of the named ERS educational formats can be found on the ERS website: https://www.ersnet.org/professional-development/cpd/cpd-thoracic-oncology. An outline of our planned thoracic oncology-specific educational formats in 2019/2020 is depicted in table 2. The educational platform of our Thoracic Oncology Assembly, with regular updates, can be viewed on the ERS website as well.

View this table:
  • View inline
  • View popup
Table 2

Activity programme

Education recognition

We aim to gain education recognition in multiple ways. First, high quality of each module should be pursued; then, we aim to obtain international, standardised quality certifications, such as CME. Such recognition is an important step in the implementation strategy and will strengthen the communication strategy, both of which are essential to reach out to as much as possible of the target audience. Similar to the successfully established sleep medicine programme [16], we strive to facilitate implementation of our educational initiative into existing national training programmes for thoracic oncology. This will allow recognition of elevating international standards in this important and rapidly changing field of respiratory medicine. It will also allow the certificate of completion of this CPD programme to be a quality-measuring instrument when employing respiratory physicians or researchers from abroad, and thus promote the transfer of knowledge inside Europe and beyond.

Communication

In an age of transition from analogue towards digital tools, a digital platform is essential to communicate with the target audience and the participants. The ERS already has an excellent basis for this activity to enhance participation and recognition of the thoracic oncology CPD programme. We envision stretching out from the ERS base to our international, national and local partners, seeking fruitful and cordial collaboration as well as avoidance of needless duplication of work. Together, we can use all digital and social media to deliver the message and the education itself. Using the available ERS communication channels, we can already be strong, but through partnership, we will be even stronger and more far reaching.

Footnotes

  • Conflict of interest: W.H. van Geffen reports a grant from Novartis (an institutional grant for an investigator-initiated trial), outside the submitted work.

  • Conflict of interest: T.G. Blum has nothing to disclose.

  • Conflict of interest: S. Aliberti reports grants and personal fees from Bayer Healthcare, Aradigm Corporation, Grifols, INSMED and Chiesi, personal fees from Astra Zeneca, Basilea, Zambon, Novartis, Raptor, Actavis UK Ltd and Horizon, outside the submitted work.

  • Conflict of interest: K.G. Blyth reports a research grant for a pre-edit and edit trial in malignant effusion, plus consultancy work, from Rocket Medical UK Ltd.

  • Conflict of interest: C. Bostantzoglou has nothing to disclose.

  • Conflict of interest: A. Farr is an employee of the European Respiratory Society.

  • Conflict of interest: B. Grigoriu has nothing to disclose.

  • Conflict of interest: G. Hardavella has nothing to disclose.

  • Conflict of interest: R.M. Huber reports personal fees from AstraZeneca Germany, Boehringer Ingelheim Germany, BMS Germany, Lilly, Pfizer Germany, Roche Germany, MSD Germany, Takeda, and Celgene, outside the submitted work.

  • Conflict of interest: N. Maskell.

  • Conflict of interest: G. Massard has nothing to disclose.

  • Conflict of interest: N.M. Rahman reports grants and personal fees from Rocket Medical UK, and personal fees from BD Medical and Lung Therapeutics USA, outside the submitted work.

  • Conflict of interest: D. Stolz has nothing to disclose.

  • Conflict of interest: J. van Meerbeeck has nothing to disclose.

  • Copyright ©ERS 2019
http://creativecommons.org/licenses/by-nc/4.0/

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. International Agency for Research on Cancer
    . Cancer today: data visualization tools for exploring the global cancer burden in 2018. http://gco.iarc.fr/today/home. Date last accessed: 23 April 2019.
  2. ↵
    1. Alt-Epping B,
    2. Staritz AE,
    3. Simon ST, et al.
    What is special about patients with lung cancer and pulmonary metastases in palliative care? Results from a nationwide survey. J Palliat Med 2012; 15: 971–977.
    OpenUrlCrossRefPubMed
    1. Ellis J
    . The impact of lung cancer on patients and carers. Chron Respir Dis 2012; 9: 39–47.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Luengo-Fernandez R,
    2. Leal J,
    3. Gray A, et al.
    Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013; 14: 1165–1174.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Barta JA,
    2. Powell CA,
    3. Wisnivesky JP
    . Global epidemiology of lung cancer. Ann Glob Health 2019; 85: 8.
    OpenUrl
  5. ↵
    1. Sun S,
    2. Schiller JH,
    3. Gazdar AF
    . Lung cancer in never smokers – a different disease. Nat Rev Cancer 2007; 7: 778–790.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Siegel RL,
    2. Miller KD,
    3. Jemal A
    . Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7–30.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Tanvetyanon T
    . Understanding the uncommon thoracic tumors. Cancer Control 2006; 13: 253.
    OpenUrl
  8. ↵
    1. Sculier JP,
    2. Vansteenkiste J,
    3. Schonfeld N, et al.
    Thoracic oncology in Europe: the ERS action plan by the Thoracic Oncology Assembly. Eur Respir J 2010; 36: 1227–1228.
    OpenUrlFREE Full Text
  9. ↵
    1. Gaga M,
    2. Powell CA,
    3. Schraufnagel DE, et al.
    An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer. Am J Respir Crit Care Med 2013; 188: 503–507.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Gamarra F,
    2. Boffetta P,
    3. De Ruysscher D, et al.
    Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe. Eur Respir J 2013; 42: 568–571.
    OpenUrlFREE Full Text
    1. Meert AP,
    2. Noel JL,
    3. Gamarra F, et al.
    The thoracic oncology specialist: curriculum recommendations in thoracic oncology training. Eur Respir J 2016; 48: 628–631.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Gamarra F,
    2. Noel JL,
    3. Brunelli A, et al.
    Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology. Breathe 2016; 12: 249–255.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Blum TG,
    2. Rich A,
    3. Baldwin D, et al.
    The European initiative for quality management in lung cancer care. Eur Respir J 2014; 43: 1254–1277.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Saarenheimo J,
    2. Eigeliene N,
    3. Andersen H, et al.
    The value of liquid biopsies for guiding therapy decisions in non-small cell lung cancer. Front Oncol 2019; 9: 129.
    OpenUrl
  14. ↵
    1. Mitchell S,
    2. Riha RL,
    3. Rohde G, et al.
    Continuing professional development: introducing the ERS International Certificate in Respiratory Sleep Medicine. Breathe 2017; 13: 11–14.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Vol 15 Issue 4 Table of Contents
Breathe: 15 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Continuous professional development: elevating thoracic oncology education in Europe
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Continuous professional development: elevating thoracic oncology education in Europe
Wouter H. van Geffen, Torsten G. Blum, Stefano Aliberti, Kevin G. Blyth, Clementine Bostantzoglou, Amy Farr, Bogdan Grigoriu, Georgia Hardavella, Rudolf M. Huber, Nick Maskell, Gilbert Massard, Najib M. Rahman, Daiana Stolz, Jan van Meerbeeck
Breathe Dec 2019, 15 (4) 279-285; DOI: 10.1183/20734735.0296-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Continuous professional development: elevating thoracic oncology education in Europe
Wouter H. van Geffen, Torsten G. Blum, Stefano Aliberti, Kevin G. Blyth, Clementine Bostantzoglou, Amy Farr, Bogdan Grigoriu, Georgia Hardavella, Rudolf M. Huber, Nick Maskell, Gilbert Massard, Najib M. Rahman, Daiana Stolz, Jan van Meerbeeck
Breathe Dec 2019, 15 (4) 279-285; DOI: 10.1183/20734735.0296-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Lung cancer
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Editorials

  • Pulmonary vascular disease for the general respiratory clinician
  • Sleep medicine in Europe: 50 years of evolution
  • Managing respiratory disease in pregnancy
Show more Editorials

Continuous professional development

  • Elevating sleep and breathing disorder education in Europe
Show more Continuous professional development

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society